.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,075,020

« Back to Dashboard

Details for Patent: 6,075,020

Title: Method of regulating immune function
Abstract:Disclosed herein is a method of treating an immune system dysfunction in a mammal by administering a prolactin reducer and a prolactin enhancer at a predetermined time or times.
Inventor(s): Cincotta; Anthony H. (Andover, MA), Meier; Albert H. (Andover, MA)
Assignee: The General Hopital Corporation (Baton Rouge, LA) The Board of Supervisors of Louisiana State University and Agricultural (Boston, MA)
Filing Date:Dec 03, 1998
Application Number:09/204,839
Claims:1. A method of treating an immune system dysfunction in a mammal suffering from said dysfunction to at least ameliorate said dysfunction comprising administering to said mammal:

a prolactin reducer only at a time or times predetermined to reduce the mammal's waking hours prolactin levels to cause the mammal's daytime prolactin profile to conform to or approach the standard daytime prolactin profile; and

a prolactin enhancer only at a time or times predetermined to increase the mammal's night time prolactin levels to cause the mammal's night time prolactin profile to conform to or approach the standard night time prolactin profile.

2. The method of claim 1 wherein said prolactin enhancer is selected from the group consisting of metoclopramide, domperidone, 5-hydroxytryptophan, haloperidol, pimozide, phenothiazine, sulpiride, chlorpromazine, serotonin agonists, pargyline, methadone, estrogens, tryptophan, melatonin, fluoxetine, dexfenfluramine, and non-toxic salts thereof.

3. The method of claim 1 wherein said prolactin reducer is a member selected from the group consisting of bromocriptine, 6-methyl-8-beta-carbobenzy-loxy-aminoethyl-10-alpha-ergoline, an 8-acylaminoergoline, ergocornine, 9,10-dihydroergocornine, a D-2-halo-6-alkyl-8-substituted ergoline, carbidopa, L-dihydroxyphenylalanine, lisuride, and pharmaceutically acceptable acid addition salts thereof.

4. The method of claim 2 wherein said prolactin enhancer is melatonin, said mammal is a human and said melatonin is administered at a predetermined time or times between about 19:00 and 1:00.

5. The method of claim 3 wherein said mammal in need of treatment is a human, said prolactin reducer is bromocriptine, and said bromocriptine is administered at a predetermined time or times between about 05:00 and 13:00.

6. A method for treating an autoimmune disease in a mammal suffering from said autoimmune disease comprising administering to said mammal:

a prolactin reducer only at a time or times predetermined to reduce the patient's daytime prolactin levels to cause the patient's daytime prolactin profile to conform to or approach the standard daytime prolactin profile; and

a prolactin enhancer only at a time or times predetermined to increase the patient's night time prolactin levels to cause the patient's night time prolactin profile to conform to or approach the standard night time prolactin profile.

7. The method of claim 6 wherein said autoimmune disease comprises rheumatoid arthritis.

8. The method of claim 6 wherein said autoimmune disease comprises Crohns disease.

9. The method of claim 6 wherein said autoimmune disease comprises lupus erythematosus.

10. The method of claim 7 wherein said prolactin enhancer is selected from the group consisting of metoclopramide, domperidone, 5-hydroxytryptophan, haloperidol, pimozide, phenothiazine, sulpiride, chlorpromazine, serotonin agonists, pargyline, methadone, estrogens, tryptophan, melatonin, fluoxetine, dexfenfluramine, and non-toxic salts thereof.

11. The method of claim 7 wherein said prolactin reducer is a member selected from the group consisting of bromocriptine, 6-methyl-8-beta-carbobenzy-loxy-aminoethyl-10-alpha-ergoline, an 8-acylaminoergoline, ergocornine, 9,10-dihydroergocornine, a D-2-halo-6-alkyl-8-substituted ergoline, carbidopa, L-dihydroxyphenylalanine, lisuride, and pharmaceutically acceptable acid addition salts thereof.

12. The method of claim 8 wherein said prolactin enhancer is selected from the group consisting of metoclopramide, domperidone, 5-hydroxytryptophan, haloperidol, pimozide, phenothiazine, sulpiride, chlorpromazine, serotonin agonists, pargyline, methadone, estrogens, tryptophan, melatonin, fluoxetine, dexfenfluramine, and non-toxic salts thereof.

13. The method of claim 8 wherein said prolactin reducer is a member selected from the group consisting of bromocriptine, 6-methyl-8-beta-carbobenzy-loxy-aminoethyl-10-alpha-ergoline, an 8-acylaminoergoline, ergocornine, 9,10-dihydroergocornine, a D-2-halo-6-alkyl-8-substituted ergoline, carbidopa, L-dihydroxyphenylalanine, lisuride, and pharmaceutically acceptable acid addition salts thereof.

14. The method of claim 12 wherein said mammal is human and said prolactin reducer is bromocriptine administered at a predetermined time or times between about 05:00 and about 13:00.

15. The method of claim 12 wherein said mammal is human and said bromocriptine is administered at a predetermined time or times between about 05:00 and about 13:00.

16. The method of claim 14 wherein said mammal is human and said prolactin reducer is bromocriptine administered at a predetermined time or times between about 05:00 and about 13:00.

17. The method of claim 15 wherein said bromocriptine is administered in an amount in the range of 0.8-8.0 mg/patient/day.

18. The method of claim 16 wherein said bromocriptine is administered in an amount in the range of 0.8-8.0 mg/patient/day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc